The toxicities associated with immunotherapy in lung cancer patients
Using checkpoint inhibitors at earlier stages of bladder cancer – the next step in immunotherapy?
A 6-factor prognostic model for urothelial carcinoma patients receiving atezolizumab
Combining immunotherapy with VEGF inhibitors to treat kidney cancer
Atezolizumab with erlotinib in combination treatment for EGFR mutant NSCLC